Navigation Links
disorder in Biological Technology

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

... the symptoms of Attention-Deficit/Hyperactivity disorder (ADHD) in children aged 6 to 12 from the first ... for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US ... ADHD. ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of ...

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

... acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced ... Hemophilia is a lifelong, inherited bleeding disorder caused by low levels or absence of a protein ... to develop a portfolio of hemophilia and bleeding disorder products that address a $7 billion market ...

REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients

... indicated for the treatment of major depressive disorder (MDD) in adults. REMERONSolTab(R) is not approved ... adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone ... and Suicide Risk Patients with major depressive disorder (MDD), both adult and pediatric, may experience ...

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment

... in adults with Attention Deficit Hyperactivity disorder (ADHD). VYVANSE is the first approved stimulant ... for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US ... have ADHD. ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of ...

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

... its once-daily Attention Deficit Hyperactivity disorder (ADHD) treatment VYVANSE (R) (lisdexamfetamine ... for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US ... ADHD. ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of ...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

... (human)) to market for a rare and devastating disorder -- hereditary angioedema (HAE). HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human ... severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human ...

BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA

... for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or ... will aid in our scientific understanding of the disorder as we further pursue this program." The ... (MPS IVA, also known as Morquio A Syndrome) is a disorder characterized by deficient activity of ...

Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL

... the treatment of Attention Deficit Hyperactivity disorder (ADHD). EQUASYM XL is approved and ... for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of ... ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of ...

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder

... of mood episodes in patients with bipolar disorder who relapsed frequently. The Agency's ... resolve any outstanding questions. Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, ...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... dimesylate) - Attention Deficit and Hyperactivity disorder ("ADHD") - The launch of VYVANSE for adult ... treatment of MLD, which is a lysosomal storage disorder that results from a deficiency in the enzyme ... its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) ...

From Pain to Unexpected Fame: One Woman's Journey to Know Fibro

... for 20 years, and when patients learn about the disorder and what types of things they can do themselves ... Fibromyalgia Fibromyalgia is a chronic pain disorder estimated to affect 2 percent of the U.S. ... and understands the challenges those with the disorder face. She has a bachelor's, a master's and a ....

FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania

... and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. ... disorder.(1) "When people think about bipolar disorder it is important to remember how debilitating the ... In fact, in the long term, patients with bipolar disorder experience depressive symptoms three times longer ...

Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program

... Deficit Hyperactivity disorder (ADHD) NEW YORK, Sept. 12 /PRNewswire/ -- The ... of patients with Attention Deficit Hyperactivity disorder (ADHD), as well as adults with ADHD, with the ... for people to learn about ADHD and how the disorder impacts people of all ages," said David Goodman, ...

CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients

... technology to help those living with a bleeding disorder to manage their condition," said Garrett ... "CSL Behring is committed to the bleeding disorder community and continues to develop creative ... Hemophilia Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous ...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

... dimesylate) - Attention Deficit and Hyperactivity disorder ("ADHD") - On April 23, 2008 Shire announced ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) ... dimesylate) (Attention Deficit and Hyperactivity disorder ("ADHD")); the impact of competitive ...

Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)

... resources about Attention Deficit Hyperactivity disorder (ADHD). The newly enhanced ADHDSupport.com ... daily activities. "ADHD is a common psychiatric disorder that can impact the lives of many people, ... and CEO of the national Attention Deficit disorder Association (ADDA), psychologist and consultant ...

Incorrectly cleaved protein leads to schizophrenia

... every year. The causes of this psychiatric disorder are not yet clear. But now, VIB researchers ... is schizophrenia? Schizophrenia is a mental disorder that appears in about 1 out of every 250 ... how the person feels. Typical symptoms of the disorder are: delusions, hallucinations, chaotic behavior, ...

Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

... of acute agitation in schizophrenic or bipolar disorder patients. Mr. Kurtz was most recently Vice ... of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed ... treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in ...

FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults

... most common emotional, cognitive and behavioral disorder treated in children(1), and according to the ... on the life span of the condition notes the disorder impairs academic, social and ... the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that ...

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

... clinical trial in patients with panic disorder in April 2008. Alexza expects to report ... of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato ... treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in ...

Shire Launches Nationwide Adult ADHD Mobile Awareness Tour

... for adults with Attention Deficit Hyperactivity disorder (ADHD), a psychiatric disorder that affects ... step toward recognizing the symptoms of the disorder by answering the 6-question World Health ... Shire is partnering with the Attention Deficit disorder Association (ADDA), a leading adult ADHD patient ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

... VYVANSE(TM) - Attention Deficit and Hyperactivity disorder ("ADHD") - By April 11, 2008 VYVANSE had ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... dimesylate) (Attention Deficit and Hyperactivity disorder ("ADHD")); the impact of competitive ...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

... the treatment of Attention Deficit Hyperactivity disorder (ADHD) in adults. VYVANSE, introduced in July ... people may think of ADHD as only a childhood disorder but the fact is that the majority of children ... and director of the Adult Attention Deficit disorder Center of Maryland. "The good news is that in a ...

CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies

... will become the main supplier of bleeding disorder treatments in the province of Quebec. CSL ... von Willebrand Disease Hemophilia is a bleeding disorder caused by a deficiency in one of the blood ... hemophilia cases. Hemophilia A is a hereditary disorder in which the clotting ability of the blood is ...

Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore

... of acute agitation in schizophrenic or bipolar disorder patients. "A key element of Alexza's ... of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato ... treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in ...

FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder

... to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping PRISTIQ to ... Major Depressive Disorder Major depressive disorder (MDD) is a common mental disorder, ... adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. -- ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder

... for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and ... adults in short-term studies of major depressive disorder and other psychiatric disorders. Patients of all ... in clinical trials for schizophrenia and bipolar disorder were dry mouth (9%-44% vs 3%-13%), sedation (30% ...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

... VYVANSE(TM) - Attention Deficit and Hyperactivity disorder ("ADHD"). - Approved by the US Food and Drug ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... dimesylate) (Attention Deficit and Hyperactivity disorder ("ADHD")); the impact of competitive ...

Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome

... Hunter syndrome (MPS II) is a serious genetic disorder mainly affecting males that interferes with the ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... on Shire's Attention Deficit and Hyperactivity disorder ("ADHD") franchise; patents, including but ...

Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder

... -- Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial ... treatment of frequently relapsing bipolar disorder (FRBD). FRBD, defined as four or more manic or ... "Patients with frequently relapsing bipolar disorder require more healthcare interventions than ...

FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients

... strengths for the attention deficit hyperactivity disorder (ADHD) treatment, VYVANSE(TM) (lisdexamfetamine ... in children and adolescents. The disorder is also estimated to affect 8.1 percent of ... U.S. adult population. ADHD is a neurobiological disorder that manifests as a persistent pattern of ...

Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation

... pharmaceutical products for this disorder and the current treatment for Celiac is complete ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... dimesylate) (Attention Deficit and Hyperactivity disorder ("ADHD")); the impact of competitive ...

New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo

... of PRISTIQ for the treatment of major depressive disorder (MDD) experienced a statistically significant ... and 100 mg in Outpatients with Major Depressive disorder in 2 Placebo-Controlled Trials Data presented ... 5:30 p.m., Eastern U.S. Time. "Major depressive disorder is a chronic and disabling disease that can cause ...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)

... (ADT) in adults with major depressive disorder (MDD). ABILIFY is the first medication approved ... this debilitating illness." Major depressive disorder affects millions of U.S. adults at some point in ... with a primary diagnosis of major depressive disorder who had experienced an inadequate response to ...

Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder

... with schizophrenia. Study overview: bipolar I disorder (presented on Tuesday, 16 October at 12:00 p.m. ... mania associated with bipolar I disorder received either asenapine (5-10 mg twice ... School of Medicine in Wichita. About bipolar disorder Bipolar disorder, commonly referred to as ...

Shire Divests Non-Core Product Portfolio to Almirall

... on building its attention deficit hyperactivity disorder (ADHD), human genetic therapies, gastrointestinal ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... on Shire's Attention Deficit and Hyperactivity disorder (ADHD) franchise; patents, including but not ...

Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome

... Hunter syndrome (MPS II) is a serious genetic disorder mainly affecting males that interferes with the ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... on Shire's Attention Deficit and Hyperactivity disorder ("ADHD") franchise; patents, including but ...

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

... to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Health care ... and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda(R) (memantine HCl), an N- ...

Celebrity Designer Ty Pennington to Host 'ADHD Experts on Call' Program

... Deficit Hyperactivity disorder (ADHD) NEW YORK, Sept. 12 /PRNewswire/ -- The ... learn more about Attention Deficit Hyperactivity disorder (ADHD) from some of the nation's top ... business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ...

Enobia Pharma Raises $40.1 Million Series B Financing

... known cure for hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone. The ... proper bone mineralization. The symptoms of the disorder include: growth retardation, skeletal deformities and frequent fractures. The disorder is lethal in its most severe form. Enobia is ...
Other Contents
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... Thompson HealthDay Reporter ... into the United States -- along with Angelina Jolie,s ... have highlighted cracks in the nation,s public health defense ... report released Thursday. Half of U.S. states are ... disease outbreaks. That was the main conclusion of the ...
(Date:12/19/2014)... The global magnetic resonance imaging (MRI) ... is saturated with numerous players developing innovative technologies. ... as non-invasive nature, MRI systems have seen continued ... healthcare market. Rapid advances in the field imaging ... have greatly expanded the potential of therapeutic applications. ...
(Date:12/19/2014)... 2014 Pain Free Living a leader ... announce a new Superior magnetic necklace using ... the strongest neodymium magnets for the fastest pain relief ... the Superior Magnetics brand for the fastest relief by ... magnetic therapy using Superior Magnetic Jewelry at fairs and ...
(Date:12/19/2014)... Slone Partners , a ... healthcare information technology, and laboratory testing industries, has ... Operating Officer. The announcement comes after a year ... strengthened presence in Boston and several new additions ... breathes the client experience," said Adam Slone, Chief ...
(Date:12/19/2014)... Consilium Staffing, Your Partner in ... for Federal Health Professionals annual meeting in Washington, ... military and federal healthcare providers. , In ... Business Engagement (NVSBE) conference last week in Atlanta, ... vital solution in addressing our nation’s shortage of ...
Breaking Medicine News(10 mins):Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2
Other TagsOther Tags